Univariate analyses of prognostic factors’ effect on TTP in all PMBCL patients (N = 159)
| Clinical feature . | P . |
|---|---|
| Age > 40 y | .89 |
| Age > 60 y | .29 |
| Bulky mass (≥10 cm) | .12 |
| B symptoms | .05 |
| PS ≥ 2 | .68 |
| Elevated LDH | .06 |
| Elevated LDH > 2× ULN | .30 |
| Extranodal sites > 1 | .02 |
| Extranodal sites > 2 | .02 |
| Stage III/IV disease | .003 |
| Pleural and/or pericardial effusion | .007 |
| Lung | .16 |
| Bone | .46 |
| Kidney/adrenal | .05 |
| IPI 0/1 vs 2/3 vs 4/5 | .02 |
| RT vs PET era | .60 |
| Clinical feature . | P . |
|---|---|
| Age > 40 y | .89 |
| Age > 60 y | .29 |
| Bulky mass (≥10 cm) | .12 |
| B symptoms | .05 |
| PS ≥ 2 | .68 |
| Elevated LDH | .06 |
| Elevated LDH > 2× ULN | .30 |
| Extranodal sites > 1 | .02 |
| Extranodal sites > 2 | .02 |
| Stage III/IV disease | .003 |
| Pleural and/or pericardial effusion | .007 |
| Lung | .16 |
| Bone | .46 |
| Kidney/adrenal | .05 |
| IPI 0/1 vs 2/3 vs 4/5 | .02 |
| RT vs PET era | .60 |
ULN, upper limit of normal.